The amount of normal-looking lung tissue visible on CT scans of the chest can help to predict survival outcomes and…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Chronic alcohol consumption damages the heart and blood vessels in ways that seem to set the stage for pulmonary…
A noninvasive intervention that makes use of ultrasound to target the splenic nerve — a nerve in the spleen, an…
The American Kidney Fund (AKF) has awarded an early-career fellowship that will support new research aiming to understand how…
Inhibikase Therapeutics is meeting with the U.S. Food and Drug Administration (FDA) April 5 to discuss the potential of…
The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the…
An inflammatory protein called CIRP may serve as a marker of pulmonary hypertension (PH) in people with chronic…
After a diagnosis of pulmonary arterial hypertension (PAH), rapidly starting treatment with a combination of therapies — both…
In people with pulmonary hypertension (PH), the endothelial cells that line the inside of blood vessels in the lungs…
People with pulmonary arterial hypertension (PAH) related to use of methamphetamine — a potent stimulant only legally available by…
A protein called SPHK2 helps to drive pulmonary hypertension (PH) by changing the epigenetic profiles of cells in blood…
The Phase 2b portion of the IMPAHCT clinical trial, which is testing multiple doses of the inhaled imatinib formulation AV-101…